DUKE UNIVERSITY COOPERATIVE CARDIOVASCULAR SOCIETY

WHO WE ARE
DUCCS supports the scholarly interests of its members by providing research and educational programs, as well as professional networking. DUCCS also serves as a resource for fellows graduating from the Duke Cardiovascular Disease Fellowship Program who are interested in developing their own clinical-research and/or education programs. We are:

- A clinical-research network comprising Duke Cardiology fellowship and faculty alumni, alumni associates, and active cardiology faculty
- Clinical and academic physicians interested in clinical research
- An international community of clinicians in 45 states and 16 countries
- A university without walls

DUCCS SUBGROUPS
DUCCS subgroup members have specific fields of interest and expertise in common. Current subgroups include:

- DAVINCI: Imaging (MRI)
- ElectroDUCCS (EP)
- Heart Failure
- OncoDUCCS (Cardio-oncology)
- Peripheral Artery Disease
- ThromboDUCCS (Clotting and anticoagulation)
- StentaDUCCS (Interventional)

OUR SERVICES

Clinical Research
- Access to clinical trials
- Physician and research coordinator recruitment assistance
- Assistance for investigator- and sponsor-initiated studies

Continuing Education
- Duke symposia
- Fellowship training program development
- DUCCS visiting professorship

Career Development/Employment
- Mentorships between fellows and graduates
- Networking events at national meetings
- Career guidance for current fellows

Alumni/Social
- Receptions and gatherings at national scientific sessions

Our Mission
To enhance the professional careers of our members through collaborative efforts in cardiovascular research and continuing education.

Why Work with the DUCCS Network?
- Comprises highly trained cardiologists interested in clinical research
- Features vetted, high-enrolling, high-quality sites
- Provides outstanding centralized site management
- Oversees site initiation development and ongoing support
DUKE UNIVERSITY COOPERATIVE CARDIOVASCULAR SOCIETY

CURRENT STUDIES

TRANSFORM-HF is a large-scale, pragmatic, randomized, unblinded clinical effectiveness study comparing torsemide versus furosemide as a treatment for heart failure. U.S. centers will enroll approximately 6,000 patients. The primary objective of the study is to compare the clinical outcomes of hospitalized patients with heart failure utilizing the treatment strategy of torsemide versus furosemide over 12 months.

Learn More: http://transformhfstudy.org/

RESEARCH HISTORY

- AFIB
- ALAN
- AMISTAD
- ATLAST
- BI-TTR
- BRIDGE
- CARB
- Dofetilide
- ENTICES
- EPIC-II
- EPILOG
- ESPIRIT
- EXCEL
- FIRST
- GUIDE IT
- The GUSTO studies
- IMPACT
- IMPACT-II
- LEXUS
- Lilly AMI
- MALHEARTS
- MTN
- MUSTT
- NIASPAN
- ORBIT
- PAC-A-TACH
- PARADIGM
- PARAGON
- PITCH HF
- PRAISE
- PRAISE-2
- PRIME
- PRIME-HF
- PROMISE
- PURSUIT
- RAID
- RELY
- RELY-ABLE
- RENAAAL
- PROMISE
- BI-TTR
- RAID
- TAO
- BRIDGE
- GUIDE IT
- PITCH HF
- Reperfusion Index
- SADHART
- Sematilide SVT
- ST LEUIS
- STAFF Studies
- STRRIDE
- SVT Pacing
- TACT
- TAO
- TOPCAT
- UTOPIA

BOARD OF DIRECTORS

President
Wayne Batchelor, MD

Vice President
Ricky Schneider, MD

Past President
Brent Muhlestein, MD

Director
Robert Meritz, MD

General Board Members
Tim Albert, MD
Alex Barbagelata, MD
Greg Barsness, MD
Melissa Burroughs Peña, MD, MS
Lauren Cooper, MD
John Heitner, MD
Rich Krasuski, MD
Marc Samsky, MD
Harry Severance, MD
Ben Steinberg, MD
Dave Whellan, MD
Mike White, MD

Duke Faculty Liaisons
James Daubert, MD
Richard Krasuski, MD
Douglas Schocken, MD

DUCCS Fellow Liaison
Stephen Greene, MD

Coordinator Representative
Wendy Schneider, RN, MSN, CCRC